Abstract
There is limited and conflicting information on the prevalence of contamination of haematopoietic stem and progenitor cell products (HPCPs), and their optimal management remains unclear. The authors reviewed the microbial surveillance data of HPCPs collected between January 2002 and December 2019 for autologous transplantation at the study institution to determine the prevalence of microbial contamination and the potential infectious complications among recipients. Among 3935 HPCPs, 25 (0.6%) were contaminated. Ultimately, 22 patients received contaminated grafts, with pre-emptive antimicrobial therapy initiated in six of these patients. No patients developed subsequent infectious complications. These data suggest that microbial contamination of autologous HPCPs and associated adverse outcomes are rare.
Highlights
Autologous haematopoietic stem cell transplantation following high-dose chemotherapy (ASCT/HDCT) is an effective option for consolidation of therapy in patients with multiple myeloma, lymphoma and acute myeloid leukaemia, and is used in patients with poor-risk germ-line tumours
Damonti et al / Journal of Hospital Infection 114 (2021) 175e179 quality control of haematopoietic stem and progenitor cell products (HPCPs) is a critical step in the transplant procedure. Previous studies assessing this issue among recipients of autologous or allogeneic grafts reported prevalence of contamination varying between 0.3% and 26.4%, predominantly involving species that are part of the normal skin flora [1e5]
3935 HPCPs were obtained from 1659 patients and cultured to rule out potential contamination
Summary
Autologous haematopoietic stem cell transplantation following high-dose chemotherapy (ASCT/HDCT) is an effective option for consolidation of therapy in patients with multiple myeloma, lymphoma and acute myeloid leukaemia, and is used in patients with poor-risk germ-line tumours. L. Damonti et al / Journal of Hospital Infection 114 (2021) 175e179 quality control of haematopoietic stem and progenitor cell products (HPCPs) is a critical step in the transplant procedure. Damonti et al / Journal of Hospital Infection 114 (2021) 175e179 quality control of haematopoietic stem and progenitor cell products (HPCPs) is a critical step in the transplant procedure Previous studies assessing this issue among recipients of autologous or allogeneic grafts reported prevalence of contamination varying between 0.3% and 26.4%, predominantly involving species that are part of the normal skin flora [1e5]. The objectives of this study were to determine the prevalence of microbial contamination in a large cohort of autologous stem cell recipients, and describe management and outcome in those recipients given contaminated products
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
